Derma Sciences

Derma Sciences is a Medical Devices company specializing in the field of Advanced Wound Care. Currently their major products are Medihoney, Algicell AG, Xtrasorb wound dressing, Bioguard and Mobility1. Their newest product DSC127 - an Angiotensin Analog - is currently in Phase II Pre-Clinical trials.
Parent Company
Integra LifeSciences
Princeton, US
Derma Sciences was founded in 1984 and is headquartered in Princeton, US

Key People at Derma Sciences

John E. Yetter

John E. Yetter

CFO & Vice President of Finance
Srini Conjeevaram

Srini Conjeevaram


Derma Sciences Office Locations

Derma Sciences has offices in Princeton and New York
Princeton, US (HQ)
300 214 Carnegie Center
New York, US
800 3rd Ave

Derma Sciences Data and Metrics

Derma Sciences Summary

Founding Date


Total Funding

$29.1 m
Derma Sciences is a subsidiary of Integra LifeSciences

Derma Sciences Financial Metrics

Derma Sciences's revenue was reported to be $84.5 m in FY, 2015 which is a 1% increase from the previous period.
USDFY, 2013FY, 2014FY, 2015


79.7 m83.7 m84.5 m

Revenue growth, %


Cost of goods sold

50.3 m53.6 m51.7 m

Gross profit

29.4 m30.1 m32.7 m

Gross profit Margin, %


R&D expense

11.3 m19.3 m807.1 k

General and administrative expense

42 m51 m51.4 m

Operating expense total

53.4 m70.2 m54.7 m


(24 m)(40.1 m)(22 m)

EBIT margin, %


Income tax expense

160.1 k(151 k)(2.2 m)

Net Income

(24 m)(39.8 m)(38.1 m)
USDFY, 2013FY, 2014FY, 2015


6.5 m19.4 m15.8 m

Accounts Receivable

7.3 m8.8 m8.1 m


16.5 m13.3 m20.7 m

Current Assets

49.5 m100.8 m71.1 m


13.5 m13.5 m13.5 m

Total Assets

88.6 m139.3 m114.8 m

Accounts Payable

4.5 m5.1 m2.5 m

Current Liabilities

9.5 m11.5 m13.5 m

Additional Paid-in Capital

140.1 m228.3 m234.9 m

Retained Earnings

(64.2 m)(103.9 m)(142 m)

Total Equity

77.1 m125.6 m98.4 m

Financial Leverage

1.1 x1.1 x1.2 x
USDFY, 2013FY, 2014FY, 2015

Net Income

(24 m)(39.8 m)(38.1 m)

Accounts Receivable

(266.8 k)(1.4 m)324.2 k


(3 m)2.6 m(9.1 m)

Accounts Payable

574.3 k679.9 k(1.6 m)

Cash From Operating Activities

(17.2 m)12.9 m(3.6 m)

Cash From Investing Activities

(20.3 m)(43.9 m)29.2 m

Cash From Financing Activities

2.6 m82.6 m1.8 m

Interest Paid

8937.8 k189

Derma Sciences Operating Metrics

FY, 2015

Patents (US)


Derma Sciences Revenue Breakdown

Derma Sciences Online and Social Media Presence

Derma Sciences News and Updates

Derma Sciences Company Life and Culture

You may also be interested in